Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/01/13 01:05:56」(JST)

wiki en

Camostat (INN) or FOY-305 is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range of uses. It is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis.^[1]^[2]^[3]^[4]^[5]^[6]

References

^ Okuno M, Kojima S, Akita K, Matsushima-Nishiwaki R, Adachi S, Sano T, Takano Y, Takai K, Obora A, Yasuda I, Shiratori Y, Okano Y, Shimada J, Suzuki Y, Muto Y, Moriwaki Y. Retinoids in liver fibrosis and cancer. Front Biosci. 2002 Jan 1;7:d204-18. PMID 11779708
^ Motoo Y. Antiproteases in the treatment of chronic pancreatitis. JOP. 2007 Jul 9;8(4 Suppl):533-7. PMID 17625311
^ Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42. PMID 18220789
^ Kitamura K, Tomita K. Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension. Clin Exp Nephrol. 2012 Feb;16(1):44-8. doi: 10.1007/s10157-011-0506-1 PMID 22038264
^ Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015 Apr;116:76-84. doi: 10.1016/j.antiviral.2015.01.011 PMID 25666761
^ Ueda M, Uchimura K, Narita Y, Miyasato Y, Mizumoto T, Morinaga J, Hayata M, Kakizoe Y, Adachi M, Miyoshi T, Shiraishi N, Kadowaki D, Sakai Y, Mukoyama M, Kitamura K. The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects. Nephron. 2015;129(3):223-32. doi: 10.1159/000375308 PMID 25766432

Kunze H, Bohn E (May 1983). "Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes". Pharmacol Res Commun 15 (5): 451–9. doi:10.1016/S0031-6989(83)80065-4. PMID 6412250.
Göke B, Stöckmann F, Müller R, Lankisch PG, Creutzfeldt W (1984). "Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion". Digestion 30 (3): 171–8. doi:10.1159/000199102. PMID 6209186.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

English Journal

Secretin is not necessary for exocrine pancreatic development and growth in mice.

Sans MD, Sabbatini ME, Ernst SA, D'Alecy LG, Nishijima I, Williams JA.SourceDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, 48109-5622, USA.
American journal of physiology. Gastrointestinal and liver physiology.Am J Physiol Gastrointest Liver Physiol.2011 Nov;301(5):G791-8. Epub 2011 Aug 18.
Adaptive exocrine pancreatic growth is mediated primarily by dietary protein and the gastrointestinal hormone cholecystokinin (CCK). Feeding trypsin inhibitors such as camostat (FOY-305) is known to induce CCK release and stimulate pancreatic growth. However, camostat has also been reported to stimu
PMID 21852360

Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension.

Kitamura K, Tomita K.SourceDepartment of Nephrology, Kumamoto University, Graduate School of Medical Sciences, 1-1-1 Honjo, Kumamoto, 860-8556, Japan, ken@gpo.kumamoto-u.ac.jp.
Clinical and experimental nephrology.Clin Exp Nephrol.2011 Nov 1. [Epub ahead of print]
Proteases are involved in numerous essential biological processes including blood clotting, controlled cell death, and tissue differentiation. Prostasin, a glycosylphosphatidylinositol-anchored serine protease, has been identified as a potential regulator of the epithelial sodium channel (ENaC) func
PMID 22038264

Japanese Journal

Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease

SAI Jin Kan,SUYAMA Masafumi,KUBOKAWA Yoshihiro,MATSUMURA Yuji,INAMI Koichi,WATANABE Sumio
Journal of gastroenterology 45(3), 335-341, 2010-03-01
NAID 10027215227

がん化学療法に伴う口内炎の予防・改善に有効な抗酸化物質の探索

鷹野瑠美,平野剛,中田千絵,笠師久美子,菅原満,小林正紀,板垣史郎,井関健
医療薬学 35(4), 247-253, 2009
… titis-associated pain is the main source of cancer treatment-related pain and in some patients it is so severe that narcotic analgesia is required.Oxidative stress may also be associated with chemotherapy-induced stomatitis and a mouthwash containing allopurinol,rebamipide and camostat for the removal of free radicals is widely used for the prevention and treatment of such stomatitis.However,such agents are not covered by the Japanese National Health Insurance scheme and there is little scientific evidence for their antioxidative properties and …
NAID 130004502536

携帯用インフュージョンポンプを用いたヘパリンの持続皮下注射が奏効した慢性播種性血管内凝固症候群の２例

戸上勝仁,永井雄也,有馬浩史,下地園子,木村隆治,井上大地,森美奈子,藤田晴之,田端淑恵,倉田雅之,柳田宗之,松下章子,永井謙一,加地修一郎,高橋隆幸
臨床血液 50(12), 1700-1705, 2009
大動脈瘤に併発する慢性播種性血管内凝固症候群（慢性DIC）は外来中心の長期治療になるため，蛋白分解酵素阻害剤の内服や高濃度ヘパリンの連日皮下注射などが行なわれるが有効性は確立していない。今回，これらの治療で慢性DICのコントロールが不良であった2例に対してヘパリンの持続皮下注射が著効を示したので報告する。症例は67歳，89歳男性で血小板数減少，著明な出血傾向のため入院。それぞれ解離性大動脈瘤，腹部 …
NAID 130004501313

Related Pictures

リーナック錠100 100mg - 添付文書Pro Online Camostat Mesilate | Certificate of Analysis Camostat Attenuates Airway Epithelial Sodium Channel Function in Vivo through the Figure 4. Chemical structure of camostat mesilate (MW: 494.53 kD). Camostat mesilate

★リンクテーブル★

リンク元	「カモスタット」
拡張検索	「camostat mesilate」

「カモスタット」

Camostat
Systematic (IUPAC) name
	N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	℞ (Prescription only);
Routes of; administration	Oral
Identifiers
CAS Number	59721-29-8 (mesylate)
ATC code	B02AB04
PubChem	CID: 2536
IUPHAR/BPS	6432
ChemSpider	2440
UNII	0FD207WKDU
ChEMBL	CHEMBL590799
Chemical data
Formula	C20H22N4O5
Molecular mass	398.41 g/mol
	SMILES CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N ;
	InChI InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) ; Key:XASIMHXSUQUHLV-UHFFFAOYSA-N ;
(verify)

　　[★]

英: camostat
化: メシル酸カモスタット camostat mesilate カモスタットメシル酸塩
商: アーチメント、カモエント、カモスタール、カモステート、カモストン、カモタット、カルモザシン、パンクレール、パンルーク、フオイパン、メシタット、メシルパン、モスパン、ラインタット、リーナック、リビリスター、レセプロン
関: 他に分類されない代謝性医薬品

蛋白分解酵素阻害薬

作用機序

フオイパン錠100mg

本剤は経口投与ですみやかに生体のキニン生成系、線溶系、凝固系及び補体系に作用し、その酵素活性をすみやかに阻害し異常亢進を抑制することにより、慢性膵炎の炎症症状と疼痛の緩解並びにアミラーゼ値の改善に効果が認められている。また、術後食道内に逆流する消化液中のトリプシンを阻害することにより、術後逆流性食道炎の改善に効果が認められている。

効能又は効果／用法及び用量